ATE286139T1 - Replikationskompetente anti-tumor vektoren - Google Patents
Replikationskompetente anti-tumor vektorenInfo
- Publication number
- ATE286139T1 ATE286139T1 AT00975153T AT00975153T ATE286139T1 AT E286139 T1 ATE286139 T1 AT E286139T1 AT 00975153 T AT00975153 T AT 00975153T AT 00975153 T AT00975153 T AT 00975153T AT E286139 T1 ATE286139 T1 AT E286139T1
- Authority
- AT
- Austria
- Prior art keywords
- vectors
- replication competent
- replication
- disclosed
- neoplastic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/351,778 US7589069B1 (en) | 1999-07-12 | 1999-07-12 | Replication-competent anti-cancer vectors |
PCT/US2000/018971 WO2001004282A2 (en) | 1999-07-12 | 2000-07-12 | Replication-competent anti-cancer vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE286139T1 true ATE286139T1 (de) | 2005-01-15 |
Family
ID=23382352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00975153T ATE286139T1 (de) | 1999-07-12 | 2000-07-12 | Replikationskompetente anti-tumor vektoren |
Country Status (9)
Country | Link |
---|---|
US (3) | US7589069B1 (de) |
EP (1) | EP1196616B1 (de) |
JP (1) | JP4361708B2 (de) |
AT (1) | ATE286139T1 (de) |
AU (1) | AU780613B2 (de) |
CA (1) | CA2378586C (de) |
DE (1) | DE60017141T2 (de) |
ES (1) | ES2231281T3 (de) |
WO (1) | WO2001004282A2 (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7589069B1 (en) * | 1999-07-12 | 2009-09-15 | Saint Louis University | Replication-competent anti-cancer vectors |
EP1377672A2 (de) | 2001-02-23 | 2004-01-07 | Novartis AG | Vektorkonstrukte |
US8163892B2 (en) * | 2002-07-08 | 2012-04-24 | Oncolys Biopharma, Inc. | Oncolytic virus replicating selectively in tumor cells |
US20040213764A1 (en) * | 2003-03-28 | 2004-10-28 | William Wold | Adenovirus replication-competent vectors expressing trail |
US7815902B2 (en) | 2003-07-09 | 2010-10-19 | Henry Ford Health System | Methods and compositions for cancer therapy using a novel adenovirus |
WO2005007109A2 (en) * | 2003-07-09 | 2005-01-27 | Henry Ford Health System | Methods and compositions for cancer therapy using a novel adenovirus |
WO2005049094A1 (en) * | 2003-11-13 | 2005-06-02 | Advantagene, Inc. | A mixed complementary viral vector for gene therapy |
JP5580043B2 (ja) * | 2007-04-27 | 2014-08-27 | オンコリスバイオファーマ株式会社 | 放射線増感増強剤 |
US8696544B2 (en) | 2009-02-05 | 2014-04-15 | Coloplast A/S | Minimally invasive adjustable support |
WO2011146885A2 (en) * | 2010-05-21 | 2011-11-24 | Virxsys Corporation | Compositions and methods for lentiviral expression of apoa-1 or variants thereof using spliceosome mediated rna trans-splicing |
EP2971008B1 (de) | 2013-03-14 | 2018-07-25 | Salk Institute for Biological Studies | Onkolytische adenoviruszusammensetzungen |
EP3390428B1 (de) | 2016-02-23 | 2019-09-25 | Salk Institute for Biological Studies | Test mit hohem durchsatz zur messung der adenovirusreplikationskinetik |
KR102471633B1 (ko) | 2016-02-23 | 2022-11-25 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
EP3551226A1 (de) | 2016-12-12 | 2019-10-16 | MultiVir Inc. | Verfahren und zusammensetzungen mit viraler gentherapie und einem immun-checkpoint-inhibitors zur behandlung und prävention von krebs und infektionskrankheiten |
AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
WO2020036635A2 (en) | 2018-03-19 | 2020-02-20 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
EP3775175A4 (de) * | 2018-04-09 | 2022-02-09 | Salk Institute for Biological Studies | Onkolytische adenoviruszusammensetzungen mit verbesserten replikationseigenschaften |
WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
US6254862B1 (en) | 1997-03-03 | 2001-07-03 | Calydon, Inc. | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
US6197293B1 (en) * | 1997-03-03 | 2001-03-06 | Calydon, Inc. | Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof |
US7589069B1 (en) * | 1999-07-12 | 2009-09-15 | Saint Louis University | Replication-competent anti-cancer vectors |
US6627190B2 (en) * | 1999-07-12 | 2003-09-30 | Saint Louis University | Recombinant adenovirus vectors that are replication-competent in tert-expressing cells |
-
1999
- 1999-07-12 US US09/351,778 patent/US7589069B1/en not_active Expired - Fee Related
-
2000
- 2000-07-12 JP JP2001509486A patent/JP4361708B2/ja not_active Expired - Fee Related
- 2000-07-12 AU AU13244/01A patent/AU780613B2/en not_active Ceased
- 2000-07-12 WO PCT/US2000/018971 patent/WO2001004282A2/en active IP Right Grant
- 2000-07-12 EP EP00975153A patent/EP1196616B1/de not_active Expired - Lifetime
- 2000-07-12 AT AT00975153T patent/ATE286139T1/de not_active IP Right Cessation
- 2000-07-12 ES ES00975153T patent/ES2231281T3/es not_active Expired - Lifetime
- 2000-07-12 CA CA2378586A patent/CA2378586C/en not_active Expired - Fee Related
- 2000-07-12 DE DE60017141T patent/DE60017141T2/de not_active Expired - Lifetime
-
2005
- 2005-10-13 US US11/249,873 patent/US7608255B2/en not_active Expired - Fee Related
-
2009
- 2009-09-16 US US12/561,016 patent/US8658610B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE60017141D1 (de) | 2005-02-03 |
DE60017141T2 (de) | 2005-12-29 |
WO2001004282A2 (en) | 2001-01-18 |
US20060029596A1 (en) | 2006-02-09 |
ES2231281T3 (es) | 2005-05-16 |
JP2003504052A (ja) | 2003-02-04 |
JP4361708B2 (ja) | 2009-11-11 |
US20100034776A1 (en) | 2010-02-11 |
EP1196616A2 (de) | 2002-04-17 |
US7589069B1 (en) | 2009-09-15 |
AU780613B2 (en) | 2005-04-07 |
AU1324401A (en) | 2001-01-30 |
CA2378586A1 (en) | 2001-01-18 |
US8658610B2 (en) | 2014-02-25 |
EP1196616B1 (de) | 2004-12-29 |
WO2001004282A3 (en) | 2001-09-13 |
CA2378586C (en) | 2011-05-03 |
US7608255B2 (en) | 2009-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60017141D1 (de) | Replikationskompetente anti-tumor vektoren | |
PT758248E (pt) | Formulacoes para o factor ix | |
DK1149905T3 (da) | Fremgangsmåder og præparat til polypeptidteknologi | |
NO950939L (no) | Defektive adenovirusvektorer og deres anvendelse i gene-terapien | |
AR020209A1 (es) | Celulosa sintetasas del maiz y usos de las mismas | |
DK1210411T3 (da) | Sammensætninger og fremgangsmåder til forbedret celledyrkning | |
ATE310829T1 (de) | Zelllinien und konstrukte für die herstellung von e1-deletierten adenoviren in abwesenheit von replikationskompetentem adenovirus | |
ATE500323T1 (de) | Subtilisin-variante | |
BRPI0412845A (pt) | herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo | |
DK1220934T3 (da) | Fremgangsmåde til fremstilling af rekombinante proteiner med anvendelse af apoptoseinhibitorer | |
HUP0101343A2 (hu) | Antitest-citokin fúziós protein által közvetített immunválasz fokozása prosztaglandin-inhibitor együttes adagolásával | |
IT8422580A0 (it) | Composizioni che le contengono e proteine di membrana cellulare, procedimento per prepararle. | |
DE69939864D1 (de) | Ppar-gamma modulatoren | |
TR200100056T2 (tr) | Nörotrofik faktörler | |
DK0996409T3 (da) | Præparat til at forsinke hårvækst og tilsvarende anvendelse | |
HUP0101352A2 (hu) | Antitest-citokin fúziós protein által közvetített immunválasz fokozása angiogenézis-inhibitor együttes adagolásával | |
DK1007537T3 (da) | Receptor-protein med betegnelsen 2F1 | |
NO20000265D0 (no) | Kontrollert cytolyse av målceller, midler og sammensetninger som forårsaker cytolyse og forbindelser som kan anvendes for å fremstille midlene | |
DE69630955D1 (de) | Immortalisierung bzw. desimmortalisierung von zellen | |
ATE285177T1 (de) | Thiole zur förderung des wachstumsvon hömatopoietischen vorläuferzellen | |
DK1121137T3 (da) | Fremgangsmåde til udryddelse af tumorer og tumorassocierede endotelceller under anvendelse af adenovirus af adenovirus-mutanter | |
DK1276763T3 (da) | Anti-fryseproteiner, deres fremstilling og anvendelse | |
ATE118310T1 (de) | Weitenverstellbare schuhkonstruktion. | |
DE69737476D1 (de) | Neuer galaninrezeptor | |
NO995959D0 (no) | Modulatorer av intracellulaer inflammasjon, celledöd og celleoverlevelsesreaksjonsveier |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |